 |
 |
 |
 |
| |
ALS Drug Development Database | Review Articles | Meeting Calendar
Please submit any new information to mleitner@prize4life.org
OR
Updated as of: September 1, 2010.
Results Found: 1
Isotechnika Pharma Inc. (Canada)
Drug Class: Small Molecule
Mechanism/Technology: Isotechnika Pharma has two programs with potential relevance to ALS therapies: (1) Non-Immunosuppressive Analog Molecules (NICAM) program, which is in preclinical development for its neuroprotective effects in stroke, AD, PD and ALS (2) TAFA93, a novel prodrug of the mTOR inhibitor, which is purported to confer neuroprotection by enhancing autophagy and currently in Phase I clinical trials.
Primary Indication: AD, PD, ALS, cancer, autoimmune diseases
Stage: Phase I, Preclinical
|
|
|
 |
|
 |
|
|
|
|
